June 2017 in “Journal of The American Academy of Dermatology” Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.
5 citations
,
August 2018 in “Neurology and Therapy” In this observational study, most patients with multiple sclerosis on teriflunomide who experienced hair thinning reported it as mild or moderate and largely recovered while continuing treatment.
6 citations
,
September 2017 in “Multiple Sclerosis and Related Disorders” This study suggests that nail loss may be a new, reversible adverse event related to teriflunomide treatment, akin to its known effects on hair loss.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.
20 citations
,
December 2016 in “Neurodegenerative disease management” This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.